Biosimilars: US and Europe COVID-19 and its economic impacts have only strengthened the case for further developing a sustainable global biosimilars market. In this Insights@CromosPharma paper we explore the development of the European biosimilar market and contrast this with the US. We also look at the key challenges and opportunities facing biosimilar developers. Read more
Clinical characteristics of dermatologic manifestations of COVID‐19 infection This article co-authored by Cromos Pharma CEO Dr Vlad Bogin and published in the International Journal of Dermatology (3 July 2020) examines the dermatologic manifestations of COVID-19. It includes a case series of 15 patients, review of literature, and proposed etiological classification. Read the full article here Read more
